Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma
Kevin C. Miller BS
Mayo Clinic School of Medicine, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorJohn P. Marinelli BS
Mayo Clinic School of Medicine, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorJamie J. Van Gompel MD
Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota
Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorMichael J. Link MD
Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota
Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorJeffrey R. Janus MD
Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorRobert L. Foote MD
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorKatharine A. Price MD
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorJoaquin Garcia MD
Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorMichael Rivera MD
Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorCorresponding Author
Ashish V. Chintakuntlawar MBBS, PhD
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota
Correspondence
Ashish V. Chintakuntlawar, Division of Medical Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905.
Email: [email protected]
Search for more papers by this authorKevin C. Miller BS
Mayo Clinic School of Medicine, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorJohn P. Marinelli BS
Mayo Clinic School of Medicine, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorJamie J. Van Gompel MD
Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota
Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorMichael J. Link MD
Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota
Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorJeffrey R. Janus MD
Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorRobert L. Foote MD
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorKatharine A. Price MD
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorJoaquin Garcia MD
Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorMichael Rivera MD
Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota
Search for more papers by this authorCorresponding Author
Ashish V. Chintakuntlawar MBBS, PhD
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota
Correspondence
Ashish V. Chintakuntlawar, Division of Medical Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905.
Email: [email protected]
Search for more papers by this authorAbstract
Background
Past research established that surgery plus adjuvant radiotherapy (S + AR) improves overall survival (OS) in esthesioneuroblastoma (ENB). However, it is unknown if the addition of adjuvant chemotherapy (AC) further improves survival. The primary objective of this study was to compare survival among patients treated with S + AR alone to patients who underwent S + AR + AC.
Methods
Retrospective review of patient records.
Results
Thirty-eight patients met inclusion criteria for either S + AR or S + AR + AC treatment groups. The S + AR + AC group contained more patients with Kadish stage D disease, dural invasion, and positive histologic margins postsurgery. All S + AR + AC patients received platinum-based regimens, combined with etoposide in 67%. OS and recurrence-free survival did not differ between the two groups, even when restricting the analysis to patients with Kadish stages B and C disease.
Conclusion
Patients who received platinum-based AC did not exhibit improved survival compared to S + AR alone. Further investigation, preferably prospective, into the optimal use of systemic therapy in ENB is warranted.
CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest with the content of this article.
Supporting Information
| Filename | Description |
|---|---|
| hed25558-sup-0001-FIgureS1.TIFTIFF image, 61.8 KB | Supplementary Figure 1 Local, regional, and distant metastases-free recurrence rates by treatment group from the date of surgery for patients meeting inclusion criteria for either adjuvant chemotherapy or control groups. (A) Local recurrence-free survival by treatment group. (B) Regional recurrence-free survival by treatment group. (C) Distant metastases-free survival by treatment group. |
| hed25558-sup-0002-FIgureS2.tifTIFF image, 57.5 KB | Supplementary Figure 2 Local, regional, and distant metastases-free recurrence rates by treatment group from the date of surgery for patients meeting inclusion criteria for either adjuvant chemotherapy or control groups, after excluding patients with Kadish stage D disease. (A) Local recurrence-free survival by treatment group. (B) Regional recurrence-free survival by treatment group. (C) Distant metastases-free survival by treatment group. |
| hed25558-sup-0003-TableS1.docxWord 2007 document , 19.5 KB | Supplementary Table 1 Comparative clinical data for the cohort of 32 Kadish Stage B and C patients who either met inclusion criteria for the adjuvant chemotherapy or control treatment group. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Berger L, Luc R, Richard D. L'esthesioneuroepitheliome olfactif. Bull Assoc Fr Etud Cancer. 1924; 13: 410-421.
- 2Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001; 2: 683-690.
- 3Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924. Anticancer Res. 1997; 17: 2683-2706.
- 4Diaz EM Jr, Johnigan RH 3rd, Pero C, et al. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck. 2005; 27: 138-149.
- 5Tajudeen BA, Arshi A, Suh JD, et al. Esthesioneuroblastoma: an update on the UCLA experience, 2002-2013. J Neurol Surg B Skull Base. 2015; 76: 43-49.
- 6Van Gompel JJ, Giannini C, Olsen KD, et al. Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival. J Neurol Surg B Skull Base. 2012; 73: 331-336.
- 7McElroy EA, Jr., Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery 1998; 42: 1023-1027; discussion 7-8.
- 8Porter AB, Bernold DM, Giannini C, et al. Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol. 2008; 90: 201-204.
- 9Hyams VJ, Batsakis JG, Michaels L, Armed Forces Institute of Pathology (U.S.). Tumors of the Upper Respiratory Tract and Ear. Washington, DC: Armed Forces Institute of Pathology; 1988.
- 10Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993; 32: 706-714; discussion 14-5.
- 11Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
- 12Kiyota N, Tahara M, Fujii S, et al. Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma. Cancer. 2008; 112: 885-891.
- 13Fitzek MM, Thornton AF, Varvares M, et al. Neuroendocrine tumors of the sinonasal tract. Cancer. 2002; 94: 2623-2634.
- 14Kim DW, Jo YH, Kim JH, et al. Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer. 2004; 101: 2257-2260.
- 15Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation: Results in 9 cases. Arch Otolaryngol Head Neck Surg. 1997; 123: 34-40.
- 16Eden BV, Debo RF, Larner JM, et al. Esthesioneuroblastoma. Long term outcome and patterns of failure—the University of Virginia experience. Cancer. 1994; 73: 2556-2562.
10.1002/1097-0142(19940515)73:10<2556::AID-CNCR2820731017>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 17El Kababri M, Habrand JL, Valteau-Couanet D, Gaspar N, Dufour C, Oberlin O. Esthesioneuroblastoma in children and adolescent: experience on 11 cases with literature review. J Pediatr Hematol Oncol. 2014; 36: 91-95.
- 18Loy AH, Reibel JF, Read PW, et al. Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg. 2006; 132: 134-138.
- 19Patil VM, Joshi A, Noronha V, et al. Neoadjuvant chemotherapy in locally advanced and borderline resectable nonsquamous sinonasal tumors (esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation). Int J Surg Oncol. 2016; 2016: 1-8.
- 20Kane AJ, Sughrue ME, Rutkowski MJ, et al. Posttreatment prognosis of patients with esthesioneuroblastoma. J Neurosurg. 2010; 113: 340-351.
- 21Boni C, Cocconi G, Bisagni G, Ceci G, Peracchia G. Cisplatin and etoposide (VP-16) as a single regimen for small cell lung cancer. A phase II trial. Cancer. 1989; 63: 638-642.
10.1002/1097-0142(19890215)63:4<638::AID-CNCR2820630406>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 22Marinelli JP, Janus JR, Van Gompel JJ, et al. Esthesioneuroblastoma with distant metastases: a systematic review & meta-analysis. Head Neck. 2018; 40: 2295-2303. https://doi.org/10.1002/hed.25209.
- 23Marinelli JP, Janus JR, Van Gompel JJ, et al. Dural invasion predicts the laterality and development of neck metastases in esthesioneuroblastoma. J Neurol Surg B Skull Base. 2018; 79: 495-500. https://doi.org/10.1055/s-0038-1625977.
- 24Czapiewski P, Kunc M, Haybaeck J. Genetic and molecular alterations in olfactory neuroblastoma: implications for pathogenesis, prognosis and treatment. Oncotarget. 2016; 7: 52584-52596.
- 25Wang L, Ding Y, Wei L, et al. Recurrent olfactory neuroblastoma treated with Cetuximab and Sunitinib: a case report. Medicine. 2016; 95: e3536.
- 26Preusser M, Hutterer M, Sohm M, et al. Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. J Neurooncol. 2010; 97: 305-308.
- 27Kim S, Atta JR, Bergmann L, Ottmann OG. Imatinib mesylate as second-line treatment in a c-kit-positive esthesioneuroblastoma. J Clin Oncol. 2011; 29: e12513-e.
- 28Dunbar EM, Pumphrey PK, Bidari S. Unexpectedly durable palliation of metastatic olfactory neuroblastoma using anti-angiogenic therapy with bevacizumab. Rare Tumors. 2012; 4: e33.
- 29Weiss GJ, Liang WS, Izatt T, et al. Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma. PLoS One. 2012; 7: e37029.
- 30Schrock A, Goke F, Wagner P, et al. Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer. Head Neck. 2014; 36: 1253-1257.
- 31Lazo de la Vega L, McHugh JB, Cani AK, et al. Comprehensive molecular profiling of olfactory neuroblastoma identifies potentially targetable FGFR3 amplifications. Mol Cancer Res. 2017; 15: 1551-1557.
- 32Gay LM, Kim S, Fedorchak K, et al. Comprehensive genomic profiling of Esthesioneuroblastoma reveals additional treatment options. Oncologist. 2017; 22: 834-842.
- 33Topcagic J, Feldman R, Ghazalpour A, Swensen J, Gatalica Z, Vranic S. Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas. PLoS One. 2018; 13: e0191244.
- 34Cha S, Lee J, Shin JY, et al. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. BMC Cancer. 2016; 16: 170.
- 35Mao L, Xia YP, Zhou YN, et al. Activation of sonic hedgehog signaling pathway in olfactory neuroblastoma. Oncology. 2009; 77: 231-243.
- 36Iyer R, Wehrmann L, Golden RL, et al. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Lett. 2016; 372: 179-186.
- 37Burki TK. Larotrectinib in TRK fusion-positive cancers. Lancet Oncol. 2018; 19(4): e187.
- 38Kim JW, Kong IG, Lee CH, et al. Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival. Otolaryngol Head Neck Surg. 2008; 139: 708-712.
- 39Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17: 883-895.
Citing Literature
